GlassScriptPhysician profile
Kevin M Gallagher
NPI 1932137767
$5,558.35
in general payments reported to CMS, 2019-2025
33 companies · $966 in 2025
The $966 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,045 · 2020: $429 · 2021: $562 · 2022: $744 · 2023: $910 · 2024: $902 · 2025: $966.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,778.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,095.58 | 2019-2025 | |
| Pfizer INC. | $939.44 | 2019-2025 | |
| Amgen INC. | $527.25 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $509.31 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $377.53 | 2019-2025 | Watchman Flx, Watchman Access System, Watchman |
| E.R. Squibb & Sons, L.L.C. | $319.73 | 2019-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $198.86 | 2021-2025 | Farxiga, Brilinta |
| Merck Sharp & Dohme LLC | $191.08 | 2024-2025 | Verquvo, Winrevair, Capvaxive |
| Actelion Pharmaceuticals US, INC. | $124.49 | 2019-2024 | Uptravi, Opsumit |
| Esperion Therapeutics, INC. | $124.20 | 2020-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $110.47 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $98.72 | 2019-2023 | Evkeeza, Praluent |
| Abbott Laboratories | $88.36 | 2023-2025 | Jot Dx, Thoratec Heartmate 3 Lvas Implant Kit |
| Jazz Pharmaceuticals INC. | $82.85 | 2019-2023 | Xywav |
| Philips North America LLC | $66.78 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $65.07 | 2023-2025 | |
| Cvrx, INC. | $63.45 | 2022-2023 | Barostim Neo System |
| Lundbeck LLC | $60.39 | 2019 | |
| Amarin Pharma, INC. | $53.67 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.63 | 2020-2022 | |
| Lilly USA, LLC | $43.89 | 2025 | Zepbound, Mounjaro |
| Arbor Pharmaceuticals, INC. | $42.68 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $41.01 | 2019 | |
| Inspire Medical Systems, INC. | $35.58 | 2025 | Inspire |
| Itamar Medical INC | $34.10 | 2022-2023 | Watchpatone |
| Baxter Healthcare | $34.10 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Bardy Diagnostics, INC. | $33.92 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $29.25 | 2023-2024 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $27.06 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $26.58 | 2021-2022 | |
| Cardiva Medical, INC. | $24.45 | 2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Avadel Cns Pharmaceuticals, LLC | $20.03 | 2025 | Lumryz |
| Atricure, INC. | $19.84 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Gallagher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.